Skip to content
sellWeak cluster of 210b5-1 plan

Daniel J. O'Connor sold $491k of AMAM

President and CEO at Ambrx Biopharma, Inc.. 50,012 shares at an average of $9.82, traded Oct 27, 2023, filed Oct 31, 2023.

Warning score
36
Value
$491k
50,012 shares
Holdings after
342,845
-13% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    CEO
    +25
  • Trade size
    $491k at market
    +18
  • Share of holdings sold
    Sold 13% of holdings
    +5
  • Cluster
    2 insiders selling within 14 days
    +8
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0000950170-23-056943, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 27, 2023SOpen-market sale
Common Stock10b5-1
-50,012$9.82$491k342,845Oct 31, 2023

Related signals

Other insiders at Ambrx Biopharma, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
21Weak
AMAMsell 210b5-1
Ambrx Biopharma, Inc.
Sonja Nelson
Chief Financial Officer
$125k
12,778 shares
-9%
30Weak
AMAMbuy
Ambrx Biopharma, Inc.
Cormorant Asset Management, LP
owner
$9.1M
1,307,311 shares
+13%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Daniel J. O'Connor sold $491k of AMAM | InsiderTell